Propanc Biopharma (PPCBD) 10-Q 14 Nov 23 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Sep. 30, 2023	Nov. 14, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--06-30
Entity File Number	000-54878
Entity Registrant Name	PROPANC BIOPHARMA, INC.
Entity Central Index Key	0001517681
Entity Tax Identification Number	33-0662986
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	302
Entity Address, Address Line Two	6 Butler Street
Entity Address, City or Town	Camberwell, VIC
Entity Address, Country	AU
Entity Address, Postal Zip Code	3124
City Area Code	+61-03
Local Phone Number	9882-0780
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		22,258,941

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Jun. 30, 2023
CURRENT ASSETS:
Cash	$ 6,625	$ 10,047
GST tax receivable	2,634	2,867
Prepaid expenses and other current assets	20,376	6,125
Refundable advance deposit	116,169
TOTAL CURRENT ASSETS	145,804	19,039
Security deposit - related party	1,928	1,999
Property and equipment, net	160	302
TOTAL ASSETS	180,371	60,328
CURRENT LIABILITIES:
Accounts payable	1,081,316	966,718
Accrued expenses and other payables	614,870	579,707
Accrued interest	52,743	44,709
Note payable, net of discount	126,000
Convertible notes, net of discounts and including put premiums	397,443	390,539
Embedded conversion option liabilities	119,069	423,209
Employee benefit liability	579,083	587,618
TOTAL CURRENT LIABILITIES	3,133,113	3,158,229
NON-CURRENT LIABILITIES:
TOTAL NON-CURRENT LIABILITIES	36,517	19,278
TOTAL LIABILITIES	3,169,630	3,177,507
Commitments and Contingencies (See Note 8)
STOCKHOLDERS’ DEFICIT:
Common stock, $0.001 par value; 10,000,000,000 shares authorized; 14,833,210 and 6,031,250 shares issued and outstanding as of September 30, 2023 and June 30, 2023, respectively	14,833	6,031
Common stock issuable (626,229 and 1,621,653 shares as of September 30, 2023 and June 30, 2023, respectively)	626	1,621
Additional paid-in capital	60,851,382	60,311,502
Accumulated other comprehensive income	1,368,550	1,294,876
Accumulated deficit	(65,178,173)	(64,684,732)
Treasury stock (0.001 share)	(46,477)	(46,477)
TOTAL STOCKHOLDERS’ DEFICIT	(2,989,259)	(3,117,179)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	180,371	60,328
Series A Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT:
Preferred stock, value
Series B Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT:
Preferred stock, value
Related Party [Member]
CURRENT ASSETS:
Operating lease right-of-use assets, net - related party	32,479	38,988
CURRENT LIABILITIES:
Loan payable	47,567	49,314
Operating lease liability - related party, current portion	21,161	21,505
Due to former director - related party	28,581	29,630
NON-CURRENT LIABILITIES:
Loan payable - long-term - related party, net of discount	23,371
Operating lease liability - long-term portion - related party	13,146	19,278
Nonrelated Party [Member]
CURRENT LIABILITIES:
Loan payable	$ 65,280	$ 65,280

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Jun. 30, 2023
Preferred stock, shares authorized	1,500,005	1,500,005
Preferred stock, par value	$ 0.01	$ 0.01
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	10,000,000,000	10,000,000,000
Common stock, shares issued	14,833,210	6,031,250
Common stock, shares outstanding	14,833,210	6,031,250
Common stock, shares issuable	626,229	1,621,653
Treasury stock price per share	$ 0.001	$ 0.001
Series A Preferred Stock [Member]
Preferred stock, shares authorized	500,000	500,000
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5	5
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	1	1
Preferred stock, shares outstanding	1	1

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
REVENUE
Revenue
OPERATING EXPENSES
Administration expenses	393,828	465,132
Occupancy expenses - related party	7,149	6,373
Research and development	16,242	101,325
TOTAL OPERATING EXPENSES	417,219	572,830
LOSS FROM OPERATIONS	(417,219)	(572,830)
OTHER INCOME (EXPENSE)
Interest expense	(178,234)	(162,752)
Interest income	17	2
Derivative expense	(77,721)
Change in fair value of derivative liabilities	303,929	65,173
Gain from settlement of accounts payable		17,499
Gain (loss) on extinguishment of debt, net	34,310	(610)
Foreign currency transaction gain (loss)	(15,948)	36,223
TOTAL OTHER INCOME (EXPENSE), NET	66,353	(44,465)
LOSS BEFORE TAXES	(350,866)	(617,295)
Tax benefit
NET LOSS	(350,866)	(617,295)
Deemed Dividend	(142,575)	(389,235)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (493,441)	$ (1,006,530)
Net loss per share available to common stockholders - basic	$ (0.04)	$ (2.13)
Net loss per share available to common stockholders - diluted	$ (0.04)	$ (2.13)
Weighted Average shares outstanding - basic	10,989,681	473,589
Weighted Average shares outstanding - diluted	10,989,681	473,589
OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized foreign currency translation gain (loss)	$ 73,674	$ 126,396
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	73,674	126,396
TOTAL COMPREHENSIVE LOSS	$ (419,767)	$ (880,134)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Common Stock Issuable [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock, Common [Member]	Total
Balance at Jun. 30, 2022	$ 5,000		$ 220	$ 20	$ 57,364,690	$ (23,758)	$ (61,557,893)	$ 1,234,549	$ (46,477)	$ (3,023,649)
Balance, shares at Jun. 30, 2022	500,000	1	220,351	19,598
Issuance of common stock for cash			$ 14		24,697	23,758				48,469
Issuance of common stock for cash, shares			14,337
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest			$ 264		456,675					456,939
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest, shares			264,493
Issuance of common stock for issuable shares			$ 20	$ (20)
Issuance of common stock for issuable shares, shares			19,597	(19,598)
Issuance of common stock for exercise of warrants					100,000					100,000
Issuance of common stock for exercise of warrants, shares			1	1
Issuance of common stock for alternate cashless exercise of warrants			$ 158		(158)
Issuance of common stock for alternate cashless exercise of warrants, shares			158,399
Reclassification of put premium upon debt conversion					133,646					133,646
Stock based compensation in connection with stock warrant grant					2,408					2,408
Warrant grant for settlement of accounts payable					5,551					5,551
Foreign currency translation gain								126,396		126,396
Deemed dividend upon alternate cashless exercise of warrants					389,235		(389,235)
Net loss							(617,295)			(617,295)
Balance at Sep. 30, 2022	$ 5,000		$ 677	$ 0	58,476,743		(62,564,423)	1,360,945	(46,477)	(2,767,535)
Balance, shares at Sep. 30, 2022	500,000	1	677,178	1
Balance at Jun. 30, 2022	$ 5,000		$ 220	$ 20	57,364,690	(23,758)	(61,557,893)	1,234,549	(46,477)	(3,023,649)
Balance, shares at Jun. 30, 2022	500,000	1	220,351	19,598
Balance at Jun. 30, 2023			$ 6,031	$ 1,621	60,311,502		(64,684,732)	1,294,876	(46,477)	(3,117,179)
Balance, shares at Jun. 30, 2023		1	6,031,250	1,621,653
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest			$ 4,899	$ 626	223,665					229,190
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest, shares			4,898,307	626,229
Issuance of common stock for issuable shares			$ 1,621	$ (1,621)
Issuance of common stock for issuable shares, shares			1,621,653	(1,621,653)
Issuance of common stock for alternate cashless exercise of warrants			$ 2,282		(2,282)
Issuance of common stock for alternate cashless exercise of warrants, shares			2,282,000
Reclassification of put premium upon debt conversion					34,838					34,838
Foreign currency translation gain								73,674		73,674
Deemed dividend upon alternate cashless exercise of warrants					142,575		(142,575)
Net loss							(350,866)			(350,866)
Relative fair value of warrant granted in connection with a loan payable - related party					141,084					141,084
Balance at Sep. 30, 2023			$ 14,833	$ 626	$ 60,851,382		$ (65,178,173)	$ 1,368,550	$ (46,477)	$ (2,989,259)
Balance, shares at Sep. 30, 2023		1	14,833,210	626,229

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (350,866)	$ (617,295)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Stock option, stock warrants and restricted stock expense		2,408
Foreign currency transaction (gain) loss	15,948	(36,223)
Depreciation expense	134	473
Amortization of debt discounts	69,457	31,275
Amortization of right-of-use assets	5,128	5,131
Change in fair value of derivative liabilities	(303,929)	(65,173)
Derivative expense	77,721
(Gain) loss on extinguishment of debt, net	(34,310)	610
Gain from settlement of accounts payable		(17,499)
Non-cash interest expense	1,437
Accretion of put premium	88,846	115,769
Changes in Assets and Liabilities:
GST receivable	132	(523)
Prepaid expenses and other assets	(14,468)	(7,747)
Refundable advance deposit	(116,169)
Accounts payable	148,834	45,121
Employee benefit liability	12,275	10,415
Accrued expenses and other payables	55,693	15,162
Accrued interest	15,712	13,430
Operating lease liability	(5,032)	(4,649)
NET CASH USED IN OPERATING ACTIVITIES	(333,457)	(509,315)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible promissory notes, net of original issue discounts and issue costs	220,000	345,750
Repayment of convertible note	(142,909)
Proceeds from the sale of common stock		24,711
Proceeds from note payable	120,000
Proceeds from loan payable - related party	153,256
Collection of subscription receivable		23,758
Proceeds from the exercise of warrants		100,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	350,347	494,219
Effect of exchange rate changes on cash	(20,312)	30,425
NET INCREASE (DECREASE) IN CASH	(3,422)	15,329
CASH AT BEGINNING OF PERIOD	10,047	4,067	$ 4,067
CASH AT END OF PERIOD	6,625	19,396	$ 10,047
Supplemental Disclosure of Cash Flow Information
Interest	2,713	2,277
Income Tax
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Reduction of put premium related to conversions of convertible notes	34,838	133,646
Conversion of convertible notes and accrued interest to common stock	114,131	349,530
Debt discounts related to derivative liability	70,000	93,668
Relative fair value of warrant granted in connection with a loan payable - related party	141,084
Warrant grant for settlement of accounts payable		23,050
Warrants issued for accrued services		5,551
Deemed dividend upon alternate cashless exercise of warrants	$ 142,575	$ 389,235

NATURE OF OPERATIONS AND SUMMAR

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	3 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) is based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of June 30, 2023, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to reflect the Company’s stage of operations and development better. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 62 granted, allowed, or accepted patents and 14 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. On May 1, 2023, the Company filed a certificate of amendment to its certificate of incorporation, as amended, to effect a one-for-one thousand (1:1,000) The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development. Basis of Presentation The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our consolidated results of operations for the three months ended September 30, 2023 and 2022 and cash flows for the three months ended September 30, 2023 and 2022 and our consolidated financial position at September 30, 2023 have been made. The Company’s results of operations for the three months ended September 30, 2023 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2024. Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2023. The June 30, 2023 balance sheet is derived from those statements. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through September 30, 2023. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly-owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency, which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). Prior to July 1, 2020, the Company recorded the foreign currency transaction gains and losses from measuring the intercompany balances as a component of other income (expenses) titled foreign currency transaction gain (loss). As of September 30, 2023 and 2022, the Company recognized a cumulative exchange gain (loss) of approximately $ 669,000 1,226,000 As of September 30, 2023 and June 30, 2023, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSACTION EXCHANGE RATES September 30, 2023 June 30, 2023 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6428 0.6664 Average exchange rate for the period USD : AUD exchange rate 0.6546 0.6732 The change in Accumulated Other Comprehensive Income by component during the three months ended September 30, 2023 was as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Balance, June 30, 2023 $ 1,294,876 Unrealized foreign currency translation gain 73,674 Ending balance, September 30, 2023 $ 1,368,550 Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 11 - Derivative Financial Instruments and Fair Value Measurements. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no Refundable Advance Deposit Refundable advance deposit of $ 116,169 0 Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE Machinery and equipment - 5 Furniture - 7 Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through September 30, 2023 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency. Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Employee Benefit/Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months. Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of September 30, 2023, and June 30, 2023, the Company was owed $ 2,634 2,867 Derivative Instruments ASC Topic 815, Derivatives and Hedging PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into shares of the Company’s common stock, par value $ 0.001 Distinguishing Liabilities from Equity Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 16,242 101,325 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as tax benefit, in operations, upon receipt. Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption. Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun. Legal Expenses All legal costs for litigation are charged to expense as incurred. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses. Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. Each holder of the notes has agreed to a 4.99 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS September 30, 2023 September 30, 2022 (Unaudited) (Unaudited) Stock Options 0.06 0.06 Stock Warrants with no designations 15,003,306 3,306 Series A Warrants as if converted at alternate cashless exercise price 1,994,343,990 2,030,790 Series B Warrants 16 26 Series C Warrants as if converted at alternate cashless exercise price * 9,175,999,954 7,499,963 Unvested restricted stock 0.06 0.06 Convertible Debt 210,849,945 884,700 Total 11,396,197,211.12 10,418,785.12 * Only convertible ratably upon exercise of Series B Warrants Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The Company is currently assessing the impact the new guidance will have on our consolidated financial statements.

GOING CONCERN

GOING CONCERN	3 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the three months ended September 30, 2023, the Company had no revenues, had a net loss of $ 350,866 333,457 2,987,309 2,989,259 65,178,173 The unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications, obtaining additional sources of suitable and adequate financing and ultimately achieving a level of sales adequate to support the Company’s cost structure and business plan. The Company’s ability to continue as a going concern is also dependent on its ability to further develop and execute on its business plan. However, there can be no assurances that any or all of these endeavors will be successful. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited)

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	3 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 – PROPERTY AND EQUIPMENT Property and equipment consist of the following As of September 30, 2023 and June 30, 2023. SCHEDULE OF PROPERTY PLANT AND EQUIPMENT September 30, 2023 June 30, 2023 (Unaudited) Office equipment at cost $ 24,532 $ 25,432 Less: Accumulated depreciation (24,372 ) (25,130 ) Total property, plant, and equipment $ 160 $ 302 Depreciation expense for the three months ended September 30, 2023 and 2022 were $ 134 473

DUE TO FORMER DIRECTOR - RELATE

DUE TO FORMER DIRECTOR - RELATED PARTY	3 Months Ended
	Sep. 30, 2023
Due To Former Director - Related Party
DUE TO FORMER DIRECTOR - RELATED PARTY	NOTE 4 – DUE TO FORMER DIRECTOR - RELATED PARTY Due to former director – related party represents unsecured advances made primarily by a former director for operating expenses on behalf of the Company, such as intellectual property and formation expenses. The expenses were paid for on behalf of the Company and are due upon demand. The Company is currently not being charged interest under these advances. The total amount owed the former director at September 30, 2023 and June 30, 2023 were $ 28,581 29,630

LOANS

LOANS	3 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
LOANS	NOTE 5 – LOANS Loan from Former Director - Related Party Loan from the Company’s former director at September 30, 2023 and June 30, 2023 were $ 47,567 49,314 Loan payable -long-term- Related Party July 5, 2023, the Company and an institutional investor affiliated with one of our directors, Josef Zelinger, entered into a letter agreement, pursuant to which such investor loaned the Company an aggregate of $ 230,000 153,256 three July 5, 2026 10 15,000,000 0.01 15,000,000 141,084 0.119 0.01 zero 3.00 4.59 268 A portion of the proceeds of such loan were used to repay an outstanding balance of approximately $ 143,000 Accrued interest from this loan amounted to $ 3,653 11,199 153,256 129,885 23,371 Loan Payable Crown Bridge Securities Purchase Agreement Effective October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge Partners, LLC (“Crown Bridge”), pursuant to which Crown Bridge purchased a convertible promissory note from the Company (the “Crown Bridge Note”), which had a remaining principal balance of $ 65,280 October 3, 2020 15 65,280 43,520 38,190 35,722 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) Loan in default The Crown Bridge Note is currently past due and in default, consisting of $ 65,280 38,190 15

NOTE PAYABLE AND CONVERTIBLE NO

NOTE PAYABLE AND CONVERTIBLE NOTES	3 Months Ended
	Sep. 30, 2023
Note Payable And Convertible Notes
NOTE PAYABLE AND CONVERTIBLE NOTES	NOTE 6 – NOTE PAYABLE AND CONVERTIBLE NOTES Promissory Note On August 15, 2023, the Company issued to an institutional investor (the “August 2023 Lender”) a 10 120,000 132,000 November 15, 2023 10 18 The Company has the right to prepay the principal and accrued but unpaid interest due under the Promissory Note, together with any other amounts that the Company may owe the August 2023 Lender under the terms of the Promissory Note, on or before September 14, 2023 at a 110% premium of the face amount plus accrued and unpaid interest and any other amounts owed to the August 2023 Lender, which increases to (i) 120% if prepaid after such date, but on or before October 14, 2023, and (ii) 130% if prepaid after October 14, 2023, unless the Company and the Lender agree to otherwise effect repayment. Accrued interest from this note amounted to $ 1,664 6,000 132,000 6,000 126,000 Convertible Notes The Company’s convertible notes outstanding at September 30, 2023 and June 30, 2023 were as follows: SCHEDULE OF CONVERTIBLE NOTES September 30, 2023 June 30, 2023 (Unaudited) Convertible notes and debenture $ 331,500 $ 338,362 Unamortized discounts (79,236 ) (38,994 ) Premium, net 145,179 91,171 Convertible notes, net $ 397,443 $ 390,539 Convertible Note Issued with Consulting Agreement Crown Bridge Securities Purchase Agreements Effective October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge, pursuant to which Crown Bridge purchased the Crown Bridge Note from the Company in the aggregate principal amount of $ 108,000 3,000 5,000 100,000 October 3, 2020 15 Additionally, Crown Bridge had the option to convert all or any amount of the Crown Bridge Note at any time after issuance until the later of such note’s maturity date or the date on which the default amount was paid if an event of default occurs, which would be between 110 150 The conversion price of the Crown Bridge Note was equal to 60% (representing a 40% discount) of the lowest closing bid price of the common stock for the ten trading days immediately prior to the delivery of a notice of conversion under such note, including the day upon which such notice was received. 4.99 9.99 72,000 The Crown Bridge Note contained certain events of default, upon which principal and accrued interest would become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal accrued at a default interest rate of 15 The total principal amount outstanding under the Crown Bridge Note was $ 65,280 7,232 42,720 28,480 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) There were 15 st 9,600 6,400 16,000 The total principal amount outstanding under the Crown Bridge Note was $ 65,280 25,930 In August 2022, the SEC filed a complaint against Crown Bridge due to its violation of Section 15(a)(1) of the Exchange Act. Crown Bridge agreed to surrender all conversion rights in its currently held convertible notes, including the Crown Bridge Note. Consequently, during fiscal year 2023, the Company reclassified the remaining principal balance of $ 65,280 43,520 0 1800 Diagonal Lending (formerly known as Sixth Street Lending) Securities Purchase Agreements June 29, 2023 Securities Purchase Agreement On June 29, 2023, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC (“1800 Diagonal”), which closed on July 6, 2023, pursuant to which 1800 Diagonal purchased a convertible promissory note (the “July 6, 2023 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 65,000 5,000 June 29, 2024 July 19, 2023 Securities Purchase Agreement On July 19, 2023, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC pursuant to which 1800 Diagonal purchased a convertible promissory note (the “July 19, 2023 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 45,000 5,000 July 19, 2024 August 16, 2023 Securities Purchase Agreement On August 16, 2023, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC pursuant to which 1800 Diagonal purchased a convertible promissory note (the “August 16, 2023 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 55,000 5,000 August 16, 2024 The following terms shall apply to all the above 1800 Diagonal notes: The 1800 Diagonal Notes bear interest at a rate of 8 During the first 60 to 180 days following the date of these notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above note, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110 129 The conversion price for the above notes shall be equal to a 35 9.99 88,846 The above notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22 Failure to deliver shares of common stock upon conversion of the above 1800 Diagonal notes within three business days of notice of conversion will result in the Company paying a penalty of $ 1,000 Upon certain events of default, the above 1800 Diagonal notes will become immediately due and payable and the Company must pay 1800 Diagonal 150 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) The total principal amount outstanding under the above 1800 Diagonal financing agreements were $ 165,000 2,488 ONE44 Capital Securities Purchase Agreements August 15, 2022 Securities Purchase Agreement On August 15, 2022, the Company entered into a securities purchase agreement with ONE44 Capital LLC, pursuant to which ONE44 Capital purchased a convertible redeemable note (the “August 15, 2022 ONE44 Note”) from the Company in the aggregate principal amount of $ 110,000 10,000 5,500 August 15, 2022 10 February 14, 2023 Securities Purchase Agreement On February 14, 2023, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “February 14, 2023 ONE44 Note”) from the Company in the aggregate principal amount of $ 111,111 11,111 5,500 10 The following terms shall apply to all of the above ONE44 note: During the first 60 to 180 days following the date of these notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to ONE44, together with any other amounts that the Company may owe ONE44 under the terms of the note, at a premium ranging from 120 135 The conversion price for the above ONE44 notes ranges from 60 65 35 40 133,305 The above ONE44 notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24 250 th 500 th 20 The total principal amount outstanding under the above ONE44 notes was $ 118,111 4,726 338,700 24,255 182,376 The total principal amount outstanding under the above ONE44 financing agreements were $ 84,500 5,861 33,611 2,136 21,510 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) GS Capital Partners Securities Purchase Agreements August 12, 2022 Securities Purchase Agreement On August 12, 2022, the Company entered into a securities purchase agreement (the “GS Capital Purchase Agreement”) with GS Capital Partners, LLC (“GS Capital”), pursuant to which GS Capital purchased a convertible redeemable note (the “GS Capital Note”) from the Company in the aggregate principal amount of $ 93,000 5,000 3,000 85,000 The maturity date of the GS Capital Note was April 12, 2023 8 The GS Capital Note was exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital by surrendering the same. GS Capital was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2.80 per share (the “Fixed Price”). However, in the event the common stock trades below $2 per share for more than five consecutive trading days, then the Fixed Price became $1.30 per share 65 4.99 Additionally, such conversion price were adjusted when the Company issued securities with more favorable conversion terms. The effective conversion price of this note was 60 40 September 21, 2022 Securities Purchase Agreement On September 21, 2022, the Company entered into a securities purchase agreement with GS Capital, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 71,500 4,000 2,500 65,000 The maturity date of such note is March 21, 2023 8 Such note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2 (the “September Fixed Price”). However, in the event the common stock trades below $1.40 per share for more than five consecutive trading days, then the September Fixed Price becomes $0.90 per share 65 4.99 Additionally, the conversion price will be adjusted in favor of the note holder if the Company issues securities with more favorable conversion terms. Currently, the effective conversion price of this note is 60 40 August 23, 2023 Securities Purchase Agreement On August 23, 2023, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note (the “GS Capital Note”) from the Company in the aggregate principal amount of $ 77,500 5,000 2,500 The maturity date of the GS Capital Note is February 23, 2024 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.04 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.02 per share in the event that the market price of the Common Stock trades below $0.03 per share for five consecutive trading days. In the event of a default under the Note and unless the Fixed Price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. Pursuant to the Note, in the event that such conversion price is below the par value of the Common Stock, the Company has agreed to take all steps to reduce such par value or conduct a reverse split of its Common Stock, as applicable. Notwithstanding the foregoing, such conversion price and lookback periods are subject to adjustment in favor of the Investor in the event the Company issues securities to another party with more favorable conversion terms, and such conversions are subject to a 4.99% beneficial ownership limitation (which may be increased to 9.9% upon 60 days’ prior written notice from the holder of the Note) and adjustments for mergers, consolidations, reorganizations and similar events set forth in the Note, other than a transfer or sale of all or substantially all Company assets. Pursuant to the Note, the Company is required to maintain an initial reserve of at least 400% of the number of Conversion Shares, subject to any increase of such reserved amount to reflect the Company’s obligations under the Note. The above GS Capital notes were bifurcated from the embedded conversion option which was recorded as derivative liabilities at fair value. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) During the first 60 to 180 days following the date of the above GS Capital notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to GS Capital, together with any other amounts that the Company may owe GS Capital under the terms of the notes, at a premium ranging from 110 125 Upon the occurrence and during the continuation of certain events of default, interest accrues at a default interest rate of 24 250 th 500 th 20 The total principal outstanding and accrued interest under the above GS Capital notes were $ 75,300 4,263 89,200 2,945 75,300 The total principal outstanding and accrued interest under the above GS Capital notes were $ 82,000 887 70,800 5,184 82,000 Coventry Enterprises, LLC Securities Purchase Agreement On November 3, 2022, the Company entered into a Securities Purchase Agreement with Coventry Enterprises, LLC (“Coventry”), pursuant to which the Company issued Coventry a promissory note from the Company in the aggregate principal amount of $ 125,000 25,000 100,000 The Coventry Note bore interest at a rate of 10 12,500 19,643 Additionally, in the event that the Company files with the SEC a qualified offering statement on Form 1-A and such note was still outstanding for four months since its issuance, Coventry had the right to convert all or portion of such note, including guaranteed interest, into shares of common stock at the offering price used in connection with such offering. At any time following an event of default under the Coventry Note, it became convertible, in whole or in part, into shares of Common Stock at the option of Coventry, at any time and from time to time thereafter (subject to the beneficial ownership limitations set forth therein). The conversion price of the Coventry Note was ninety percent (90%) per share of the lowest per-share VWAP during the twenty (20) trading-day period before the conversion (each, a “Calculated Conversion Price”). In the event that, within 30 calendar days either before or after any conversion, the conversion price of which was based upon a Calculated Conversion Price, the Company consummates (in whole or in part) any financing (whether such financing was equity, equity-equivalent, or debt or any combination thereof) or for any other reason issues any shares of common stock or any common stock equivalents at a price less than the most recent Calculated Conversion Price (the “Alternative Conversion Price”), regardless of when that note or instrument was originated, then, at the option of Coventry, (i) if the conversion had not yet occurred, then the Alternative Conversion Price will be substituted for the Calculated Conversion Price and (ii) if the conversion had occurred, then, within two trading days following Coventry’s written request, the Company was required to issue to Coventry that number of shares of Common Stock equivalent to the difference between the number of shares of Common Stock that had been issued using the Calculated Conversion Price and the number of shares of Common Stock that would have been issued using the Alternative Conversion Price. Accordingly, the Coventry note is treated as stock settled debt under ASC 480 and the Company recorded a total of $ 13,889 Upon the occurrence and during the continuation of certain events of default, interest on the Coventry Note accrues at a default interest rate equal to the lesser of (i) 18% per annum or (ii) the maximum rate permitted by law. Subject to the beneficial ownership limitation in the Coventry Note, if any event of default occurs, then the outstanding principal amount guaranteed interest plus accrued but unpaid default rate interest, liquidated damages and other amounts owing on the Coventry Note through the date of acceleration became immediately due and payable at Coventry’s option, in cash or in shares of common stock at the mandatory default amount, which was equal to 120% of all such amounts due on the Coventry Note. If the Company failed to deliver to Coventry such shares, the Company was required to pay in cash an amount equal to the amount that the value of such shares exceeds the principal amount and interest of the attempted conversion. As an additional inducement to Coventry entering into such agreement, the Company issued to Coventry 75,000 37,500 The Company failed to make the first installment payment due in March 2023 which was considered an event of default. The Company recorded a default penalty of $ 25,000 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) The total principal amount outstanding and accrued interest under the above Coventry note was $ 144,951 5,049 22,749 561 In July 2023, the Company fully paid the remaining principal including accrued interest for a total of $ 142,979 0 5,049 2,043 357 13,328 Convertible notes in default None of the outstanding convertible notes above were in default as of September 30, 2023. Amortization of debt discounts The Company recorded $ 92,500 127,418 88,846 115,769 Amortization of debt discounts associated with convertible notes for the three months ended September 30, 2023 and 2022 was $ 52,258 31,275 The Company reclassified $ 34,838 133,646

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	3 Months Ended
	Sep. 30, 2023
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 7 – STOCKHOLDERS’ DEFICIT Increase in Authorized Shares of Common Stock and Reverse Stock Split On May 18, 2022, the board of directors of the Company approved and authorized, and the holders of a majority-in-interest of the Company’s voting capital stock approved by written consent for the Company to file a certificate of amendment to its certificate of incorporation, as amended (the “Certificate of Incorporation”), which increased the Company’s authorized capital stock. Such certificate of amendment increased the number of authorized shares of common stock from 1,000,000,000 3,000,000,000 1,500,005 3,001,500,005 On September 21, 2022, the board of directors of the Company approved and authorized, and the holders of a majority-in-interest of the Company’s voting capital stock approved by written consent for the Company to file a certificate of amendment to its Certificate of Incorporation, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of common stock from 3,000,000,000 10,000,000,000 1,500,005 10,001,500,005 On May 1, 2023, the Company filed a certificate of amendment to its certificate of incorporation, as amended, to effect a one-for-one thousand (1:1,000) Preferred Stock The total number of shares of preferred stock that the Company is authorized to issue is 1,500,005 0.01 Of the total preferred shares authorized, 500,000 On March 15, 2023, the Company filed a certificate with the Secretary of State of Delaware (the “Certificate of Retirement”), effecting the retirement and cancellation of the Series A Preferred Stock to eliminate such Series A Preferred Stock. No PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) Pursuant to a certificate of designation filed with the Secretary of State of the State of Delaware on June 16, 2015, five shares of preferred stock have been designated as Series B Preferred Stock, par value $ 0.01 One No Common Stock: Shares issued for conversion of convertible debt From July 1, 2023 through September 30, 2023, the Company issued an aggregate of 4,898,307 626,229 0.02 106,454 7,677 1,437 229,190 113,622 626,229 Included in the above conversions during the three months ended September 30, 2023, convertible notes with principal aggregate amount of $ 70,800 5,184 1,437 191,043 113,622 147,932 34,310 The Company reclassified $ 34,838 The Company has 3,818,041,727 Shares issued for issuable shares As of June 30, 2023, there was common stock issuable of 1,621,653 1,621,653 Shares issued for exercise of warrants During the three months ended September 30, 2023, the Company issued an aggregate of 2,282,000 0.0114 200,000 0.001 The Alternate Cashless Exercise provision, for a cashless conversion at the holder’s option, is available should the trading price of the Company’s common stock fall below $ 200,000 70 142,575 Restricted Stock Units Pursuant to employment agreements dated in May 2019, the Company granted an aggregate of 0.078 0.039 0.117 0.117 4,250,000 497,240 248,620 0.06 248,620 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) Stock Warrants: The following table summarizes warrant activity for the three months ended September 30, 2023: SCHEDULE OF WARRANT ACTIVITY Weighted Number of Average Shares Price Per Share Outstanding at June 30, 2023 3,396 $ 5,440 Granted 15,000,000 0.01 Exercised - - Forfeited - - Expired - - Outstanding at September 30, 2023 15,003,396 * $ 1.24 Exercisable at September 30, 2023 15,003,378 $ 1.24 Outstanding and Exercisable: Weighted average remaining contractual term 2.76 Aggregate intrinsic value $ - * The total warrants of 15,003,396 SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 10 10 Series B warrants 17 17 Series C warrants 64 46 Warrants with no class designation 15,003,305 15,003,305 Total 15,003,396 15,003,378 Exercise of Warrants During the three months ended September 30, 2023, the Company issued an aggregate of 2,282,000 0.0114 200,000 0.001 Warrants Granted to Lender – Related Party July 5, 2023, the Company and an institutional investor affiliated with one of our directors, Josef Zelinger, entered into a letter agreement, pursuant to which such investor loaned the Company an aggregate of $ 230,000 153,256 three July 5, 2026 10 15,000,000 0.01 15,000,000 141,084 0.119 0.01 zero 3.00 4.59 268 Stock Options: A summary of the Company’s option activity during the three months ended September 30, 2023 is presented below: SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY Weighted Number of Average Exercise Shares Price Per Share Outstanding at June 30, 2023 0.059 $ 4,533,000 Granted - - Exercised - - Forfeited - - Expired - - Outstanding at September 30, 2023 0.059 $ 4,533,000 Exercisable at September 30, 2023 0.059 $ 4,533,000 Outstanding and Exercisable: Weighted average remaining contractual term 5.62 Weighted average fair value of options granted during the period $ - Aggregate intrinsic value $ - PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) On the Effective Date, the Company’s board of directors approved and adopted the Company’s 2019 Equity Incentive Plan (the “2019 Plan”), which reserves a total of 234 During the three months ended September 30, 2023 and 2022, the Company recognized stock-based compensation of $ 0 0 No

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 – COMMITMENTS AND CONTINGENCIES Legal Matters From time to time, the Company may be subject to litigation and claims arising in the ordinary course of business. The Company is not currently a party to any material legal proceedings and the Company is not aware of any pending or threatened legal proceeding against the Company that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition. IRS Liability As part of its requirement for having a foreign operating subsidiary, the Company’s parent U.S. entity is required to file an informational Form 5471 to the Internal Revenue Service (the “IRS”), which is a form that explains the nature of the relationship between the foreign subsidiary and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely filings, the Company incurred a penalty from the IRS in the amount of $ 10,000 30,000 Operating Agreements In November 2009, the Company entered into a commercialization agreement with the University of Bath (UK) (the “UK University”), whereby the Company and the UK University co-owned the intellectual property relating to the Company’s pro-enzyme formulations. In June 2012, the Company and the UK University entered into an assignment and amendment whereby the Company assumed full ownership of the intellectual property, while agreeing to pay royalties of 2 5 Collaboration Agreement On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”) to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 52,000 59,508 40,000 45,775 2 On October 1, 2020, the Company entered into another two-year collaboration agreement with the University to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 30,000 35,145 5,000 5,000 5,858 10,000 11,715 10,000 11,715 25,837 30,268 2 On July 27, 2022, the Company entered into a two-year research agreement with the University to provide certain research and experiment services to the Company. One of the Company’s Scientific Advisory Board is the lead joint researcher of the University. In exchange for full ownership of the intellectual property, the Company agreed to pay royalties of 1% of net revenues each to two members of the Scientific Advisory Board. In consideration of such services, the Company agreed to pay the University approximately 53,200 53,806 - 18,200 18,407 - 8,000 8,091 - 7,000 7,080 - 10,000 10,114 - 10,000 10,114 The commencement date for the experiments was on September 1, 2022, and the estimated length of time for completion is 24 months. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) As of September 30, 2023 and June 30, 2023, the Company has $ 24,446 18,056 no Consulting Agreement On July 1, 2022, the Company and a consultant agreed to extend the term of a consulting agreement from July 1, 2022 to June 30, 2023 to provide media-related services for a monthly fee of $ 50,000 9.9 9.9 73,301 608,423 0 Operating Lease – Related Party On May 4, 2022, the Company entered in a three 3,000 2,176 66,201 66,201 8 ROU is summarized below: SCHEDULE OF RIGHT OF USE ASSET September 30, 2023 June 30, 2023 Office lease $ 66,201 $ 66,201 Less: accumulated amortization (33,722 ) (27,213 ) Right-of-use asset, net $ 32,479 $ 38,988 Operating Lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY September 30, 2023 June 30, 2023 Office lease $ 66,201 $ 66,201 Reduction of lease liability (31,894 ) (25,418 ) Less: office lease, current portion (21,161 ) (21,505 ) Long term portion of lease liability $ 13,146 $ 19,278 Remaining future minimum lease payments under non-cancelable operating lease at September 30, 2023 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2024 $ 17,356 Fiscal Year 2025 19,284 Imputed interest (2,333 ) Total operating lease liability $ 34,307 The weighted average remaining lease term for the operating lease is 1.52

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS Since its inception, the Company has conducted transactions with its directors and entities related to such directors. These transactions have included the following: As of September 30, 2023 and June 30, 2023, the Company owed its former director a total of $ 28,581 29,630 As of September 30, 2023 and June 30, 2023, the Company owed its former director a total of $ 47,567 49,314 Effective May 5, 2016, the Company entered into an agreement for the lease of its principal executive offices with North Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our CEO, CFO and a director, and his wife are owners and directors. The lease had a five 39,600 28,325 3,600 2,575 198,000 141,629 Such lease expired in May 2021 and was renewed for another one-year term from May 2021 to May 2022 three 3,000 2,176 167,129 107,430 158,129 105,377 7,149 6,373 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) Loan payable -long-term- Related Party July 5, 2023, the Company and an institutional investor affiliated with one of our directors, Josef Zelinger, entered into a letter agreement, pursuant to which such investor loaned the Company an aggregate of $ 230,000 153,256 three 10 15,000,000 0.01 Employment and Services Agreements with Management The Company and Mr. Nathanielsz entered into an employment agreement as of February 25, 2015 (the “Nathanielsz Employment Agreement”) setting forth the terms and conditions of Mr. Nathanielsz’s employment as the Company’s President and Chief Executive Officer. The Nathanielsz Employment Agreement was scheduled to expire on February 25, 2019 25,000 300,000 205,680 9.5 200 300,000 205,680 400,000 274,240 400,000 309,313 600,000 414,900 Mr. Nathanielsz’s wife, Sylvia Nathanielsz, is and has been a non-executive, part-time employee of the Company since October 2015. Effective February 1, 2018, Mrs. Nathanielsz receives an annual salary of $ 120,000 80,904 Pursuant to a February 25, 2016 board resolution, James Nathanielsz was paid $ 4,481 3,205 7,689 5,577 On August 12, 2021, the Board approved a bonus of $ 177,840 221,890 166,418 422,610 316,957 177,840 5,928,000 140,000 96,810 144,166 99,691 181,324 125,386 73,387 48,905 107,937 71,929 25,000 16,070 82,937 53,312 Amended and Restated Employment Agreement On May 14, 2019 (the “Effective Date”), the Company entered into an Amended and Restated Employment Agreement (the “Employment Agreement”) with Mr. Nathanielsz for a term of three years 400,000 309,313 0.04 4,675,000 110 4,250,000 0.04 0.04 10 0.04 0.04 On October 26, 2022, the Company entered into an Amended and Restated Employment Agreement (the “Amended Agreement”) with Mr. Nathanielsz, effective as of July 1, 2022, (the “2022 Effective Date”). The Amended Agreement provides Mr. Nathanielsz with a base salary of $ 600,000 414,900 100 200 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) Amended and Restated Employment Agreement On May 14, 2019, the Company entered into an Amended and Restated Services Agreement (the “Services Agreement”) with Dr. Kenyon, the Company’s Chief Scientific Officer and a director, for a term of three years 54,000 41,580 0.02 4,250,000 100 0.02 0.02 10 0.02 0.02 On August 12, 2021, pursuant to a Cancellation Agreement, Mr. Kenyon agreed to cancel accrued salaries of $ 102,600 3,420 107,500 69,101 96,000 64,627 Intercompany Loans All intercompany loans were made by the parent to the Company’s subsidiary, Propanc PTY LTD, none of which has been repaid as of September 30, 2023. Effective fiscal year 2021, the parent company determined that intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment on the condensed consolidated balance sheet as accumulated other comprehensive income.

CONCENTRATIONS AND RISKS

CONCENTRATIONS AND RISKS	3 Months Ended
	Sep. 30, 2023
Risks and Uncertainties [Abstract]
CONCENTRATIONS AND RISKS	NOTE 10 – CONCENTRATIONS AND RISKS Concentration of Credit Risk The Company maintains its cash in banks and financial institutions in Australia. Bank deposits in Australian banks are uninsured. The Company has not experienced any losses in such accounts through September 30, 2023. The Company primarily relied on funding from four convertible and non-convertible debt lenders and received net proceeds after deductions of $ 34,500 150,000 70,000 120,000 153,256 30 14 24 32 The Company primarily relied on funding from three convertible debt lenders and received net proceeds after deductions of $ 33,750 101,250 94,500 150,000 29 27 44 Receivable Concentration As of September 30, 2023 and June 30, 2023, the Company’s receivables were 100 Patent and Patent Concentration The Company has filed multiple patent applications relating to its lead product, PRP. The Company’s lead patent application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Republic of Korea, India and Brazil. In Canada and Mexico, the patent applications have been accepted as of fiscal year 2023. In 2016 and early 2017, the Company filed other patent applications. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in over 150 countries. Once filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national phase. One of the PCT applications filed in November 2016, entered national phase in July 2018 and another PCT application entered national phase in August 2018. A third PCT application entered the national phase in October 2018. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 62 granted, allowed, or accepted patents and 14 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. Further patent applications are expected to be filed to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) Foreign Operations As of September 30, 2023 and June 30, 2023, the Company’s operations are based in Camberwell, Australia; however, the majority of research and development is being conducted in the European Union. On July 22, 2016, the Company formed a wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales, for the purpose of submitting an orphan drug application with the European Medicines Agency as a small and medium-sized enterprise. As of September 30, 2023 and June 30, 2023, there has been no activity within this entity.

DERIVATIVE FINANCIAL INSTRUMENT

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	3 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	NOTE 11 - DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Derivative Financial Instruments: The Company applies the provisions of ASC 815-40, Contracts in Entity’s Own Equity 82,000 75,300 The Company calculates the estimated fair values of the liabilities for derivative instruments using the Binomial Trees Method. The closing price of the Company’s common stock at September 30, 2023, the last trading day of the period ended September 30, 2023, was $ 0.024 Convertible Debt SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES Initial Valuations into during the three September 30, 2023 Volatility 327.58 % 328 % Expected Remaining Term (in years) 0.50 0.40 0.47 Risk Free Interest Rate 5.55 % 5.53 % Expected dividend yield None None Fair Value Measurements: The Company measures and reports at fair value the liability for derivative instruments. The fair value liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing the Binomial Trees model. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2023 and June 30, 2023: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at September 30, 2023 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 119,069 $ — $ — $ 119,069 Total $ 119,069 $ — $ — $ 119,069 Balance at June 30, 2023 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 423,209 $ — $ — $ 423,209 Total $ 423,209 $ — $ — $ 423,209 The following is a roll forward for the three months ended September 30, 2023 of the fair value liability of price adjustable derivative instruments: PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2023 $ 423,209 Beginning balance $ 423,209 Initial fair value of embedded conversion option derivative liability recorded as debt discount 70,000 Initial fair value of embedded conversion option derivative liability recorded as derivative expense 77,721 Reduction of derivative liability upon debt conversion (147,932 ) Change in fair value included in statements of operations (303,929 ) Balance at September 30, 2023 $ 119,069 Ending balance $ 119,069

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS Shares issued for conversion of convertible debt Between October 2023 and November 2023, the Company issued an aggregate of 6,059,502 0.001 37,800 2,354 160 22,200 Shares issued for exercise of warrants In October 2023, the Company issued 740,000 0.0037 12,160 Issuance of convertible notes October 20, 2023 Securities Purchase Agreement On October 20, 2023, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC pursuant to which 1800 Diagonal purchased a convertible promissory note (the “October 20, 2023 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 40,000 5,000 October 20, 2024 The following terms shall apply to the above 1800 Diagonal note: The 1800 Diagonal Notes bear interest at a rate of 8 During the first 60 to 180 days following the date of these notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above note, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110 129 The conversion price for the above notes shall be equal to a 35 9.99 The above notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22 1,000 150 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) GS Capital Partners, LLC Securities Purchase Agreement On October 12, 2023, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note (the “GS Capital Note”) from the Company in the aggregate principal amount of $ 61,000 3,500 2,500 The maturity date of the GS Capital Note is April 12, 2024 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.015 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.01 per share in the event that the market price of the Common Stock trades below $0.0075 per share for ten consecutive trading days. In the event of a default under the Note and unless the Fixed Price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. Pursuant to the Note, in the event that such conversion price is below the par value of the Common Stock, the Company has agreed to take all steps to reduce such par value or conduct a reverse split of its Common Stock, as applicable. Notwithstanding the foregoing, such conversion price and lookback periods are subject to adjustment in favor of the Investor in the event the Company issues securities to another party with more favorable conversion terms, and such conversions are subject to a 4.99% beneficial ownership limitation (which may be increased to 9.9% upon 60 days’ prior written notice from the holder of the Note) and adjustments for mergers, consolidations, reorganizations and similar events set forth in the Note, other than a transfer or sale of all or substantially all Company assets. Pursuant to the Note, the Company is required to maintain an initial reserve of at least 400% of the number of Conversion Shares, subject to any increase of such reserved amount to reflect the Company’s obligations under the Note During the first 60 to 180 days following the date of this note, the Company has the right to prepay the principal and accrued but unpaid interest due under the above note issued to GS Capital, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110 125 Upon the occurrence and during the continuation of certain events of default, interest shall accrue at a default interest rate of 24 250 th 500 th 20 The above GS Capital note will be bifurcated from the embedded conversion option which shall be recorded as derivative liabilities at fair value.

NATURE OF OPERATIONS AND SUMM_2

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Policies)	3 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) is based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of June 30, 2023, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to reflect the Company’s stage of operations and development better. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 62 granted, allowed, or accepted patents and 14 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. On May 1, 2023, the Company filed a certificate of amendment to its certificate of incorporation, as amended, to effect a one-for-one thousand (1:1,000) The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development.
Basis of Presentation	Basis of Presentation The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our consolidated results of operations for the three months ended September 30, 2023 and 2022 and cash flows for the three months ended September 30, 2023 and 2022 and our consolidated financial position at September 30, 2023 have been made. The Company’s results of operations for the three months ended September 30, 2023 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2024. Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2023. The June 30, 2023 balance sheet is derived from those statements.
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through September 30, 2023.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited)
Foreign Currency Translation and Other Comprehensive Income (Loss)	Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly-owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency, which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). Prior to July 1, 2020, the Company recorded the foreign currency transaction gains and losses from measuring the intercompany balances as a component of other income (expenses) titled foreign currency transaction gain (loss). As of September 30, 2023 and 2022, the Company recognized a cumulative exchange gain (loss) of approximately $ 669,000 1,226,000 As of September 30, 2023 and June 30, 2023, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSACTION EXCHANGE RATES September 30, 2023 June 30, 2023 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6428 0.6664 Average exchange rate for the period USD : AUD exchange rate 0.6546 0.6732 The change in Accumulated Other Comprehensive Income by component during the three months ended September 30, 2023 was as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Balance, June 30, 2023 $ 1,294,876 Unrealized foreign currency translation gain 73,674 Ending balance, September 30, 2023 $ 1,368,550
Fair Value of Financial Instruments and Fair Value Measurements	Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited) Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 11 - Derivative Financial Instruments and Fair Value Measurements.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no
Refundable Advance Deposit	Refundable Advance Deposit Refundable advance deposit of $ 116,169 0
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE Machinery and equipment - 5 Furniture - 7
Patents	Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through September 30, 2023 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.
Employee Benefit/Liability	Employee Benefit/Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months.
Australian Goods and Services Tax (“GST”)	Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of September 30, 2023, and June 30, 2023, the Company was owed $ 2,634 2,867
Derivative Instruments	Derivative Instruments ASC Topic 815, Derivatives and Hedging PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited)
Convertible Notes With Variable Conversion Options	Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into shares of the Company’s common stock, par value $ 0.001 Distinguishing Liabilities from Equity
Income Taxes	Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes
Research and Development Costs and Tax Credits	Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 16,242 101,325 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as tax benefit, in operations, upon receipt.
Stock Based Compensation	Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption.
Revenue Recognition	Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun.
Legal Expenses	Legal Expenses All legal costs for litigation are charged to expense as incurred. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 (Unaudited)
Leases	Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses.
Basic and Diluted Net Loss Per Common Share	Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. Each holder of the notes has agreed to a 4.99 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS September 30, 2023 September 30, 2022 (Unaudited) (Unaudited) Stock Options 0.06 0.06 Stock Warrants with no designations 15,003,306 3,306 Series A Warrants as if converted at alternate cashless exercise price 1,994,343,990 2,030,790 Series B Warrants 16 26 Series C Warrants as if converted at alternate cashless exercise price * 9,175,999,954 7,499,963 Unvested restricted stock 0.06 0.06 Convertible Debt 210,849,945 884,700 Total 11,396,197,211.12 10,418,785.12 * Only convertible ratably upon exercise of Series B Warrants
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The Company is currently assessing the impact the new guidance will have on our consolidated financial statements.

NATURE OF OPERATIONS AND SUMM_3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Tables)	3 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
SCHEDULE OF TRANSACTION EXCHANGE RATES	As of September 30, 2023 and June 30, 2023, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSACTION EXCHANGE RATES September 30, 2023 June 30, 2023 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6428 0.6664 Average exchange rate for the period USD : AUD exchange rate 0.6546 0.6732
SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS	The change in Accumulated Other Comprehensive Income by component during the three months ended September 30, 2023 was as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Balance, June 30, 2023 $ 1,294,876 Unrealized foreign currency translation gain 73,674 Ending balance, September 30, 2023 $ 1,368,550
SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE	The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE Machinery and equipment - 5 Furniture - 7
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS	SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS September 30, 2023 September 30, 2022 (Unaudited) (Unaudited) Stock Options 0.06 0.06 Stock Warrants with no designations 15,003,306 3,306 Series A Warrants as if converted at alternate cashless exercise price 1,994,343,990 2,030,790 Series B Warrants 16 26 Series C Warrants as if converted at alternate cashless exercise price * 9,175,999,954 7,499,963 Unvested restricted stock 0.06 0.06 Convertible Debt 210,849,945 884,700 Total 11,396,197,211.12 10,418,785.12 * Only convertible ratably upon exercise of Series B Warrants

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	Property and equipment consist of the following As of September 30, 2023 and June 30, 2023. SCHEDULE OF PROPERTY PLANT AND EQUIPMENT September 30, 2023 June 30, 2023 (Unaudited) Office equipment at cost $ 24,532 $ 25,432 Less: Accumulated depreciation (24,372 ) (25,130 ) Total property, plant, and equipment $ 160 $ 302

NOTE PAYABLE AND CONVERTIBLE _2

NOTE PAYABLE AND CONVERTIBLE NOTES (Tables)	3 Months Ended
	Sep. 30, 2023
Note Payable And Convertible Notes
SCHEDULE OF CONVERTIBLE NOTES	The Company’s convertible notes outstanding at September 30, 2023 and June 30, 2023 were as follows: SCHEDULE OF CONVERTIBLE NOTES September 30, 2023 June 30, 2023 (Unaudited) Convertible notes and debenture $ 331,500 $ 338,362 Unamortized discounts (79,236 ) (38,994 ) Premium, net 145,179 91,171 Convertible notes, net $ 397,443 $ 390,539

STOCKHOLDERS_ DEFICIT (Tables)

STOCKHOLDERS’ DEFICIT (Tables)	3 Months Ended
	Sep. 30, 2023
Equity [Abstract]
SCHEDULE OF WARRANT ACTIVITY	The following table summarizes warrant activity for the three months ended September 30, 2023: SCHEDULE OF WARRANT ACTIVITY Weighted Number of Average Shares Price Per Share Outstanding at June 30, 2023 3,396 $ 5,440 Granted 15,000,000 0.01 Exercised - - Forfeited - - Expired - - Outstanding at September 30, 2023 15,003,396 * $ 1.24 Exercisable at September 30, 2023 15,003,378 $ 1.24 Outstanding and Exercisable: Weighted average remaining contractual term 2.76 Aggregate intrinsic value $ - * The total warrants of 15,003,396
SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE	SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 10 10 Series B warrants 17 17 Series C warrants 64 46 Warrants with no class designation 15,003,305 15,003,305 Total 15,003,396 15,003,378
SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY	A summary of the Company’s option activity during the three months ended September 30, 2023 is presented below: SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY Weighted Number of Average Exercise Shares Price Per Share Outstanding at June 30, 2023 0.059 $ 4,533,000 Granted - - Exercised - - Forfeited - - Expired - - Outstanding at September 30, 2023 0.059 $ 4,533,000 Exercisable at September 30, 2023 0.059 $ 4,533,000 Outstanding and Exercisable: Weighted average remaining contractual term 5.62 Weighted average fair value of options granted during the period $ - Aggregate intrinsic value $ -

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF RIGHT OF USE ASSET	ROU is summarized below: SCHEDULE OF RIGHT OF USE ASSET September 30, 2023 June 30, 2023 Office lease $ 66,201 $ 66,201 Less: accumulated amortization (33,722 ) (27,213 ) Right-of-use asset, net $ 32,479 $ 38,988
SCHEDULE OF OPERATING LEASE LIABILITY	Operating Lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY September 30, 2023 June 30, 2023 Office lease $ 66,201 $ 66,201 Reduction of lease liability (31,894 ) (25,418 ) Less: office lease, current portion (21,161 ) (21,505 ) Long term portion of lease liability $ 13,146 $ 19,278
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS	Remaining future minimum lease payments under non-cancelable operating lease at September 30, 2023 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2024 $ 17,356 Fiscal Year 2025 19,284 Imputed interest (2,333 ) Total operating lease liability $ 34,307

DERIVATIVE FINANCIAL INSTRUME_2

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES	SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES Initial Valuations into during the three September 30, 2023 Volatility 327.58 % 328 % Expected Remaining Term (in years) 0.50 0.40 0.47 Risk Free Interest Rate 5.55 % 5.53 % Expected dividend yield None None
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS	SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at September 30, 2023 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 119,069 $ — $ — $ 119,069 Total $ 119,069 $ — $ — $ 119,069 Balance at June 30, 2023 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 423,209 $ — $ — $ 423,209 Total $ 423,209 $ — $ — $ 423,209
SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE	SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2023 $ 423,209 Beginning balance $ 423,209 Initial fair value of embedded conversion option derivative liability recorded as debt discount 70,000 Initial fair value of embedded conversion option derivative liability recorded as derivative expense 77,721 Reduction of derivative liability upon debt conversion (147,932 ) Change in fair value included in statements of operations (303,929 ) Balance at September 30, 2023 $ 119,069 Ending balance $ 119,069

SCHEDULE OF TRANSACTION EXCHANG

SCHEDULE OF TRANSACTION EXCHANGE RATES (Details)	Sep. 30, 2023	Jun. 30, 2023
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.6428	0.6664
Weighted Average [Member]
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.6546	0.6732

SCHEDULE OF ACCUMULATED OTHER C

SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS (Details)	3 Months Ended
	Sep. 30, 2023 USD ($)
Accounting Policies [Abstract]
Beginning balance	$ 1,294,876
Unrealized foreign currency translation gain	73,674
Ending balance	$ 1,368,550

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE (Details)	Sep. 30, 2023
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment	7 years

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS (Details) - shares		3 Months Ended
		Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		11,396,197,211.12	10,418,785.12
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		0.06	0.06
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		15,003,306	3,306
Series A Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		1,994,343,990	2,030,790
Series B Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		16	26
Series C Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	[1]	9,175,999,954	7,499,963
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		0.06	0.06
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		210,849,945	884,700
[1]Only convertible ratably upon exercise of Series B Warrants

NATURE OF OPERATIONS AND SUMM_4

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Details Narrative) - USD ($)		3 Months Ended
	May 01, 2023	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
Short-Term Debt [Line Items]
Reverse stock split	one-for-one thousand (1:1,000)
Cash and cash equivalents		$ 0		$ 0
Refundable advance deposit		116,169
GST tax receivable		$ 2,634		$ 2,867
Common stock, par value		$ 0.001		$ 0.001
Research and development costs		$ 16,242	$ 101,325
Beneficial ownership conversion description		Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance.
Beneficial ownership percentage		4.99%
Intercompany Loans [Member]
Short-Term Debt [Line Items]
Foreign currency transaction, gain		$ 669,000	$ 1,226,000

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 350,866	$ 617,295
Net Cash Provided by (Used in) Operating Activities	333,457	509,315
Working capital deficit	2,987,309
Stockholders equity	2,989,259	$ 2,767,535	$ 3,117,179	$ 3,023,649
Retained earnings accumulated deficit	$ 65,178,173		$ 64,684,732

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Office equipment at cost	$ 24,532	$ 25,432
Less: Accumulated depreciation	(24,372)	(25,130)
Total property, plant, and equipment	$ 160	$ 302

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation	$ 134	$ 473

DUE TO FORMER DIRECTOR - RELA_2

DUE TO FORMER DIRECTOR - RELATED PARTY (Details Narrative) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Due to related parties current	$ 28,581	$ 29,630

LOANS (Details Narrative)

LOANS (Details Narrative)				1 Months Ended	3 Months Ended		12 Months Ended
	Jul. 05, 2023 USD ($) $ / shares shares	Nov. 03, 2022 USD ($)	Oct. 03, 2019	Jul. 31, 2023 USD ($)	Sep. 30, 2023 USD ($) $ / shares	Sep. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jul. 05, 2023 AUD ($)	Jun. 30, 2022 USD ($)	Nov. 30, 2020 USD ($)
Debt instrument face amount					$ 70,800
Debt instrument interest rate stated percentage	10%							10%
Settlement of convertible debt					142,909
Interest payable current and non current					5,184
Amortization of debt discounts					69,457	31,275
Proceeds from loan payable - related party					153,256
Remaining debt discount					331,500		$ 338,362
Gain on extinguishment of debt					34,310	(610)
Crown Bridge Partners, LLC [Member]
Debt instrument face amount					$ 65,280
Debt instrument interest rate stated percentage					15%
Interest payable current and non current					$ 38,190
Warrant [Member]
Stock valuation price per share | $ / shares					$ 0.119
Warrant exercise price | $ / shares					$ 0.01
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Volatility					0
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Volatility					4.59
Warrant [Member] | Measurement Input, Price Volatility [Member]
Volatility					268
Letter Agreement [Member]
Debt instrument face amount	$ 153,256							$ 230,000
Maturity term	3 years
Maturity date	Jul. 05, 2026
Debt instrument interest rate stated percentage	10%							10%
Issue of warrants | shares	15,000,000
Share price | $ / shares	$ 0.01
Fair value adjustment of warrants	$ 141,084
Letter Agreement [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]
Settlement of convertible debt					$ 143,000
Letter Agreement [Member] | Warrant [Member]
Stock valuation price per share | $ / shares	$ 0.119
Warrant exercise price | $ / shares	$ 0.01
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Volatility	0							0
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Expected Term [Member]
Maturity term	3 years
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Volatility	4.59							4.59
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Price Volatility [Member]
Volatility	268							268
Securities Purchase Agreement [Member]
Debt instrument face amount							65,280
Maturity date			Oct. 03, 2020
Amortization of debt discounts					92,500	$ 127,418
Securities Purchase Agreement [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]
Debt instrument interest rate stated percentage		10%
Settlement of convertible debt				$ 142,979
Interest payable current and non current					2,043		22,749
Amortization of debt discounts		$ 37,500
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member]
Debt instrument face amount							65,280		$ 65,280	$ 9,600
Maturity date			Oct. 03, 2020
Debt instrument interest rate stated percentage			15%
Interest payable current and non current					38,190		35,722		$ 25,930
Convertible debt					65,280
Gain on extinguishment of debt							43,520
Related Party [Member]
Loan payable					47,567		49,314
Interest payable current and non current					3,653
Amortization of debt discounts					11,199
Remaining debt discount					129,885
Loan payable - long-term - related party, net of discount					$ 23,371

SCHEDULE OF CONVERTIBLE NOTES (

SCHEDULE OF CONVERTIBLE NOTES (Details) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Note Payable And Convertible Notes
Convertible notes and debenture	$ 331,500	$ 338,362
Unamortized discounts	(79,236)	(38,994)
Premium, net	145,179	91,171
Convertible notes, net	$ 397,443	$ 390,539

NOTE PAYABLE AND CONVERTIBLE _3

NOTE PAYABLE AND CONVERTIBLE NOTES (Details Narrative) - USD ($)														1 Months Ended	3 Months Ended		12 Months Ended
	Aug. 23, 2023	Aug. 16, 2023	Aug. 15, 2023	Jul. 19, 2023	Jul. 06, 2023	Feb. 15, 2023	Feb. 14, 2023	Nov. 03, 2022	Sep. 21, 2022	Aug. 15, 2022	Aug. 12, 2022	Sep. 16, 2020	Oct. 03, 2019	Jul. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Jun. 30, 2020	Jul. 05, 2023	Jun. 30, 2022	Dec. 07, 2021	Nov. 30, 2020
Short-Term Debt [Line Items]
Principal amount															$ 70,800
Debt instrument, interest rate, stated percentage																			10%
Interest payable current and non current															5,184
Amortization of debt discount															69,457	$ 31,275
Proceeds from loan payable - related party															153,256
Remaining debt discount															331,500		$ 338,362
Note payable, net of discount															126,000
Original issue discount															79,236		38,994
Proceeds from convertible debt															220,000	345,750
Debt instrument debt default interest rate	24%
Settled debt premium															145,179		91,171
Gain on extinguishment of debt															34,310	(610)
Penalty amount															30,000
Original issue discounts amount															$ 34,500	33,750
Lowest trading price percentage															4.99%
Derivative liabilities															$ 119,069		423,209
Additional debt issued															229,190	456,939
Settlement of convertible debt															142,909
Conversion of Stock, Amount Converted															34,838	133,646
Convertible Notes [Member]
Short-Term Debt [Line Items]
Amortization of debt discount															52,258	31,275
Crown Bridge Partners, LLC [Member]
Short-Term Debt [Line Items]
Principal amount															$ 65,280
Debt instrument, interest rate, stated percentage															15%
Interest payable current and non current															$ 38,190
ONE44 Capital LLC [Member]
Short-Term Debt [Line Items]
Interest payable current and non current															2,136		24,255
Settled debt premium																	133,305
GS Capital Partners, LLC [Member]
Short-Term Debt [Line Items]
Interest payable current and non current															5,184		2,945
Coventry Enterprises LLC Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Monthly payment amount								$ 19,643
Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Principal amount																	65,280
Debt instrument maturity date													Oct. 03, 2020
Amortization of debt discount															92,500	127,418
Original issue discount															88,846	$ 115,769
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member]
Short-Term Debt [Line Items]
Principal amount																	65,280			$ 65,280		$ 9,600
Debt instrument maturity date													Oct. 03, 2020
Debt instrument, interest rate, stated percentage													15%
Debt instrument description													The conversion price of the Crown Bridge Note was equal to 60% (representing a 40% discount) of the lowest closing bid price of the common stock for the ten trading days immediately prior to the delivery of a notice of conversion under such note, including the day upon which such notice was received.
Interest payable current and non current															38,190		35,722			$ 25,930
Original issue discount													$ 5,000
Proceeds from convertible debt													$ 100,000
Debt instrument debt default interest rate													15%
Settled debt premium													$ 72,000				13,889					6,400
Unissued shares conversion												15
Equity conversion																						$ 16,000
Gain on extinguishment of debt																	43,520
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate													110%
Percentage of outstanding shares of common stock													4.99%
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate													150%
Percentage of outstanding shares of common stock													9.99%
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member]
Short-Term Debt [Line Items]
Principal amount													$ 108,000					$ 65,280
Debt instrument principal payment													$ 3,000
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | August 2019 Auctus Note [Member]
Short-Term Debt [Line Items]
Interest payable current and non current																		7,232
Settled debt premium																		28,480
Convertible debt principal amount																		$ 42,720
Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate, stated percentage		800%
Interest payable current and non current															2,488
Debt instrument debt default interest rate		35%
Percentage of outstanding shares of common stock		150%
Convertible debt principal amount															165,000
Debt instrument settlement debt amount		$ 88,846
Debt outstanding principal percentage		22%
Penalty amount		$ 1,000
Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate		110%
Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate		129%
Percentage of outstanding shares of common stock		9.99%
Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | July Six Twenty Twenty Three Thousand Eighthundred Diagonal Note [Member]
Short-Term Debt [Line Items]
Principal amount					$ 65,000
Debt instrument maturity date					Jun. 29, 2024
Debt issuance costs					$ 5,000
Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | July Nineteen Twenty Twenty Three Thousand Eighthundred Diagonal Note [Member]
Short-Term Debt [Line Items]
Principal amount				$ 45,000
Debt instrument maturity date				Jul. 19, 2024
Debt issuance costs				$ 5,000
Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | August Sixteen Twenty Twenty Three Thousand Eighthundred Diagonal Note [Member]
Short-Term Debt [Line Items]
Principal amount		$ 55,000
Debt instrument maturity date		Aug. 16, 2024
Debt issuance costs		$ 5,000
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member]
Short-Term Debt [Line Items]
Principal amount							$ 111,111								84,500		118,111				$ 110,000
Debt instrument maturity date										Aug. 15, 2022
Debt instrument, interest rate, stated percentage							10%			10%
Interest payable current and non current															5,861		4,726
Settled debt premium															21,510		182,376
Convertible debt principal amount															33,611		338,700
Debt outstanding principal percentage						24%
Original issue discounts amount							$ 11,111			$ 10,000
Legal fees							$ 5,500			$ 5,500
Debt instrument debt default interest rate									60%		60%
Debt instrument discount rate									40%		40%
Debt principal increase percentage							20%
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate							120%
Penalty amount							$ 250
Debt instrument debt default interest rate							60%
Debt instrument discount rate							35%
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate							135%
Penalty amount							$ 500
Debt instrument debt default interest rate							65%
Debt instrument discount rate							40%
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]
Short-Term Debt [Line Items]
Principal amount	$ 77,500								$ 71,500		$ 93,000				82,000		75,300
Debt instrument maturity date	Feb. 23, 2024								Mar. 21, 2023		Apr. 12, 2023
Debt instrument, interest rate, stated percentage	8%								8%		8%
Interest payable current and non current															887		4,263
Original issue discount	$ 5,000								$ 4,000		$ 5,000
Percentage of outstanding shares of common stock									4.99%		4.99%
Legal fees	$ 2,500								$ 2,500		$ 3,000
Debt principal increase percentage	20%
Proceeds from Issuance of Debt									$ 65,000		$ 85,000
Conversion price, description	The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.04 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.02 per share in the event that the market price of the Common Stock trades below $0.03 per share for five consecutive trading days. In the event of a default under the Note and unless the Fixed Price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. Pursuant to the Note, in the event that such conversion price is below the par value of the Common Stock, the Company has agreed to take all steps to reduce such par value or conduct a reverse split of its Common Stock, as applicable. Notwithstanding the foregoing, such conversion price and lookback periods are subject to adjustment in favor of the Investor in the event the Company issues securities to another party with more favorable conversion terms, and such conversions are subject to a 4.99% beneficial ownership limitation (which may be increased to 9.9% upon 60 days’ prior written notice from the holder of the Note) and adjustments for mergers, consolidations, reorganizations and similar events set forth in the Note, other than a transfer or sale of all or substantially all Company assets. Pursuant to the Note, the Company is required to maintain an initial reserve of at least 400% of the number of Conversion Shares, subject to any increase of such reserved amount to reflect the Company’s obligations under the Note.								Such note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2 (the “September Fixed Price”). However, in the event the common stock trades below $1.40 per share for more than five consecutive trading days, then the September Fixed Price becomes $0.90 per share		The GS Capital Note was exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital by surrendering the same. GS Capital was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2.80 per share (the “Fixed Price”). However, in the event the common stock trades below $2 per share for more than five consecutive trading days, then the Fixed Price became $1.30 per share
Lowest trading price percentage									65%		65%
Derivative liabilities															82,000		75,300
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate	110%
Penalty amount	$ 250
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate	125%
Penalty amount	$ 500
Securities Purchase Agreement [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate, stated percentage								10%
Interest payable current and non current															2,043		22,749
Amortization of debt discount								$ 37,500
Original issue discount								25,000
Proceeds from convertible debt								100,000
Convertible debt principal amount								125,000
Debt instrument guaranteed interest								$ 12,500
Number of shares issued								75,000
Debt Default penalty																	25,000
Amount of convertible debt outstanding with penalty														$ 0			144,951
Amount repaid for covertible debt															5,049		5,049
Additional debt issued															13,328		561
Settlement of convertible debt														$ 142,979
Interest payable current and non current															357
Crown Bridge Financing Agreement [Member] | Crown Bridge Partners, LLC [Member]
Short-Term Debt [Line Items]
Principal amount																	0
August 10, 2017 Consulting Agreement [Member] | GS Capital Partners, LLC [Member]
Short-Term Debt [Line Items]
Convertible debt principal amount															70,800		$ 89,200
Loans Payable [Member]
Short-Term Debt [Line Items]
Debt instrument original issue discount rate			10%
Debt instrument, discount amount			$ 120,000
Principal amount			$ 132,000
Debt instrument maturity date			Nov. 15, 2023
Debt instrument, interest rate, stated percentage			10%
Debt instrument increase interest rate			18%
Debt instrument description			The Company has the right to prepay the principal and accrued but unpaid interest due under the Promissory Note, together with any other amounts that the Company may owe the August 2023 Lender under the terms of the Promissory Note, on or before September 14, 2023 at a 110% premium of the face amount plus accrued and unpaid interest and any other amounts owed to the August 2023 Lender, which increases to (i) 120% if prepaid after such date, but on or before October 14, 2023, and (ii) 130% if prepaid after October 14, 2023, unless the Company and the Lender agree to otherwise effect repayment.
Interest payable current and non current															1,664
Amortization of debt discount															6,000
Proceeds from loan payable - related party															132,000
Remaining debt discount															$ 6,000

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details)	3 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Equity [Abstract]
Number of Shares, Outstanding, Beginning balance | shares	3,396
Weighted Average Price Per Share, Outstanding, Beginning balance | $ / shares	$ 5,440
Number of Shares, Granted | shares	15,000,000
Weighted Average Price Per Share, Granted | $ / shares	$ 0.01
Number of Shares, Exercised | shares
Weighted Average Price Per Share, Exercised | $ / shares
Number of Shares, Forfeited | shares
Weighted Average Price Per Share, Forfeited | $ / shares
Number of Shares, Expired | shares
Weighted Average Price Per Share, Expired | $ / shares
Number of Shares, Outstanding, Ending balance | shares	15,003,396	[1]
Weighted Average Price Per Share, Outstanding, Ending balance | $ / shares	$ 1.24
Number of Shares, Exercisable, Ending balance | shares	15,003,378
Weighted Average Price Per Share, Exercisable, Ending balance | $ / shares	$ 1.24
Weighted average remaining contractual term	2 years 9 months 3 days
Aggregate intrinsic value | $
[1]The total warrants of 15,003,396

SCHEDULE OF WARRANT ACTIVITY (P

SCHEDULE OF WARRANT ACTIVITY (Parenthetical) (Details) - shares	Sep. 30, 2023		Jun. 30, 2023
Equity [Abstract]
Number of Shares, Outstanding, Ending balance | shares	15,003,396	[1]	3,396
[1]The total warrants of 15,003,396

SCHEDULE OF WARRANT OUTSTANDING

SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE (Details) - shares	Sep. 30, 2023		Jun. 30, 2023
Class of Stock [Line Items]
Number of Warrants, Total	15,003,396	[1]	3,396
Exercisable, Total	15,003,378
Series A Warrants [Member]
Class of Stock [Line Items]
Number of Warrants, Total	10
Exercisable, Total	10
Series B Warrants [Member]
Class of Stock [Line Items]
Number of Warrants, Total	17
Exercisable, Total	17
Series C Warrants [Member]
Class of Stock [Line Items]
Number of Warrants, Total	64
Exercisable, Total	46
Warrants With No Class Designation [Member]
Class of Stock [Line Items]
Number of Warrants, Total	15,003,305
Exercisable, Total	15,003,305
[1]The total warrants of 15,003,396

SCHEDULE OF SHARE BASED COMPENS

SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY (Details)	3 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Equity [Abstract]
Number of Shares, Outstanding, Beginning balance | shares	0.059
Weighted Average Price Per Share, Outstanding, Beginning balance	$ 4,533,000
Number of Shares, Granted | shares
Weighted Average Price Per Share, Granted
Number of Shares, Exercised | shares
Weighted Average Price Per Share, Exercised
Number of Shares, Forfeited | shares
Weighted Average Price Per Share, Forfeited
Number of Shares, Expired | shares
Weighted Average Price Per Share, Expired
Number of Shares, Outstanding, Ending balance | shares	0.059
Weighted Average Price Per Share, Outstanding, Ending balance	$ 4,533,000
Number of Shares, Exercisable, Ending balance | shares	0.059
Weighted Average Price Per Share, Exercisable, Ending balance	$ 4,533,000
Weighted average remaining contractual term	5 years 7 months 13 days
Weighted average fair value of options granted during the period
Aggregate intrinsic value | $

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative)

1 Months Ended

3 Months Ended

12 Months Ended

Jul. 05, 2023 USD ($) $ / shares shares

May 01, 2023

Oct. 03, 2019

Jul. 31, 2023 shares

May 31, 2019 USD ($) $ / shares shares

Sep. 30, 2023 USD ($) $ / shares shares

Sep. 30, 2022 USD ($) $ / shares

Jun. 30, 2023 USD ($) $ / shares shares

Nov. 30, 2023 USD ($)

Oct. 31, 2023 $ / shares

Oct. 03, 2023 shares

Jul. 05, 2023 AUD ($)

Mar. 31, 2023 shares

Sep. 21, 2022 shares

Sep. 20, 2022 shares

May 18, 2022 shares

May 17, 2022 shares

Class of Stock [Line Items]

Common Stock, Shares Authorized

10,000,000,000

10,000,000,000

10,000,000,000

3,000,000,000

3,000,000,000

1,000,000,000

Number of preferred stock authorized shares

1,500,005

1,500,005

Total number of authorized shares

10,001,500,005

3,001,500,005

Stockholders equity reverse stock split

one-for-one thousand (1:1,000)

Preferred stock, shares authorized

1,500,005

1,500,005

Preferred stock, par value | $ / shares

$ 0.01

$ 0.01

Warrants exercised

14,833,210

6,031,250

Investor loan, value | $

$ 70,800

Accrued interest | $

5,184

Conversion fees | $

1,437

Proceeds from issuance of common stock | $

$ 24,711

Loss on extinguishment debt conversion | $

113,622

Derivative liability fair value | $

147,932

Gain (loss) on extinguishment of debt | $

34,310

(610)

Conversion of Stock, Amount Converted | $

34,838

133,646

Deemed dividend | $

$ 142,575

Restricted stock units, value | $ / shares

Debt instrument interest rate

10%

10%

Share based compensation | $

$ 0

$ 0

Unvested stock option expense | $

$ 0

Stock options granted

0

2019 Equity Incentive Plan [Member]

Class of Stock [Line Items]

Number of common shares reserved for future issuance

234

Warrant [Member]

Class of Stock [Line Items]

Stock valuation price per share | $ / shares

$ 0.119

Warrant exercise price | $ / shares

$ 0.01

Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Volatility

0

Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Volatility

4.59

Warrant [Member] | Measurement Input, Price Volatility [Member]

Class of Stock [Line Items]

Volatility

268

Warrant [Member] | Affiliated Entity [Member]

Class of Stock [Line Items]

Warrants to purchase common stock

15,000,000

Warrant [Member] | Affiliated Entity [Member] | Measurement Input, Expected Term [Member]

Class of Stock [Line Items]

Maturity term

3 years

Restricted Stock Units (RSUs) [Member]

Class of Stock [Line Items]

Restricted stock units, shares

0.117

Restricted stock units, value | $ / shares

$ 4,250,000

Fair value granted, shares | $

$ 497,240

Unrecognized restricted stock units expense | $

$ 248,620

$ 248,620

Restricted stock units not yet vested, shares | $

$ 248,620

Unvested Restricted Stock Units [Member]

Class of Stock [Line Items]

Unvested restricted stock units

0.06

0.06

Series A And C Warrant [Member]

Class of Stock [Line Items]

Issuance of stock

2,282,000

Series A Warrants [Member]

Class of Stock [Line Items]

Warrants exercised

2,282,000

Share price | $ / shares

$ 0.0114

Warrants exercise price | $ / shares

200,000

$ 200,000

Alternate cashless warrant exercise price | $ / shares

$ 0.001

Percentage of exercise price and market price

70%

Warrants to purchase common stock

0.0114

Chief Executive Officer [Member]

Class of Stock [Line Items]

Restricted stock units, shares

0.078

Chief Scientific Officer [Member]

Class of Stock [Line Items]

Restricted stock units, shares

0.039

Consultant Services [Member] | Consultant Three [Member]

Class of Stock [Line Items]

Warrants exercised

1,621,653

Stock issued during period shares

1,621,653

Underlying Financing Agreements [Member]

Class of Stock [Line Items]

Number of common shares reserved for future issuance

3,818,041,727

Letter Agreement [Member]

Class of Stock [Line Items]

Investor loan, value

$ 153,256

$ 230,000

Share price | $ / shares

$ 0.01

Maturity term

3 years

Debt instrument maturity date

Jul. 05, 2026

Debt instrument interest rate

10%

10%

Issue of warrants

15,000,000

Fair value adjustment of warrants | $

$ 141,084

Letter Agreement [Member] | Warrant [Member]

Class of Stock [Line Items]

Stock valuation price per share | $ / shares

$ 0.119

Warrant exercise price | $ / shares

$ 0.01

Letter Agreement [Member] | Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Volatility

0

0

Letter Agreement [Member] | Warrant [Member] | Measurement Input, Expected Term [Member]

Class of Stock [Line Items]

Maturity term

3 years

Letter Agreement [Member] | Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Volatility

4.59

4.59

Letter Agreement [Member] | Warrant [Member] | Measurement Input, Price Volatility [Member]

Class of Stock [Line Items]

Volatility

268

268

Securities Purchase Agreement [Member]

Class of Stock [Line Items]

Investor loan, value | $

$ 65,280

Debt instrument maturity date

Oct. 03, 2020

Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member]

Class of Stock [Line Items]

Fair value adjustment of warrants | $

$ 141,084

Subsequent Event [Member]

Class of Stock [Line Items]

Investor loan, value | $

$ 37,800

Accrued interest | $

2,354

Conversion fees | $

$ 160

Convertible Debt [Member]

Class of Stock [Line Items]

Issuance of stock

4,898,307

Warrants exercised

626,229

Average contractual conversion prices | $ / shares

$ 0.02

Investor loan, value | $

$ 106,454

Accrued interest | $

7,677

Conversion fees | $

1,437

Proceeds from issuance of common stock | $

229,190

Proceeds from issuance of shares under stock options | $

113,622

Debt instrument fair value | $

$ 191,043

Convertible Debt [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Volatility

5.53

Convertible Debt [Member] | Measurement Input, Price Volatility [Member]

Class of Stock [Line Items]

Volatility

328

Convertible Debt [Member] | Subsequent Event [Member]

Class of Stock [Line Items]

Warrants exercised

626,229

Series A Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

500,000

500,000

Preferred stock, par value | $ / shares

$ 0.01

$ 0.01

Preferred stock shares outstanding

0

0

0

Preferred stock shares issued

0

0

Series B Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

5

5

Preferred stock, par value | $ / shares

$ 0.01

$ 0.01

Preferred stock shares outstanding

1

1

Preferred stock shares issued

1

1

Shares, Issued

0

0

Series A Warrant [Member]

Class of Stock [Line Items]

Warrants exercise price | $ / shares

$ 200,000

Series A Warrant [Member] | Subsequent Event [Member]

Class of Stock [Line Items]

Alternate cashless warrant exercise price | $ / shares

$ 0.0037

SCHEDULE OF RIGHT OF USE ASSET

SCHEDULE OF RIGHT OF USE ASSET (Details) - Related Party [Member] - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Defined Benefit Plan Disclosure [Line Items]
Office lease	$ 66,201	$ 66,201
Less: accumulated amortization	(33,722)	(27,213)
Right-of-use asset, net	$ 32,479	$ 38,988

SCHEDULE OF OPERATING LEASE LIA

SCHEDULE OF OPERATING LEASE LIABILITY (Details) - Related Party [Member] - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Defined Benefit Plan Disclosure [Line Items]
Office lease	$ 66,201	$ 66,201
Reduction of lease liability	(31,894)	(25,418)
Less: office lease, current portion	(21,161)	(21,505)
Long term portion of lease liability	$ 13,146	$ 19,278

SCHEDULE OF FUTURE MINIMUM LEAS

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)	Sep. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Fiscal Year 2024	$ 17,356
Fiscal Year 2025	19,284
Imputed interest	(2,333)
Total operating lease liability	$ 34,307

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)

1 Months Ended

3 Months Ended

12 Months Ended

Nov. 16, 2022 shares

Jul. 27, 2022 USD ($)

Jul. 27, 2022 EUR (€)

Jul. 01, 2022 USD ($)

May 04, 2022 USD ($)

May 04, 2022 AUD ($)

Oct. 01, 2020 USD ($)

Oct. 01, 2020 EUR (€)

Sep. 13, 2018 USD ($)

Sep. 13, 2018 EUR (€)

Jul. 31, 2023 USD ($)

Jul. 31, 2023 EUR (€)

Mar. 31, 2023 USD ($)

Mar. 31, 2023 EUR (€)

Dec. 31, 2022 USD ($)

Dec. 31, 2022 EUR (€)

Sep. 30, 2022 USD ($)

Sep. 30, 2022 EUR (€)

Aug. 31, 2022 USD ($)

Aug. 31, 2022 EUR (€)

Dec. 31, 2021 USD ($)

Dec. 31, 2021 EUR (€)

Mar. 31, 2021 USD ($)

Mar. 31, 2021 EUR (€)

Nov. 30, 2020 EUR (€)

Jun. 30, 2012

Sep. 30, 2023 USD ($)

Sep. 30, 2022 USD ($)

Jun. 30, 2023 USD ($)

Total litigation penalty amount

$ 30,000

Royalties percentage

2%

2%

unreimbursed lab fees

24,446

$ 18,056

Royalty fees

0

$ 0

Accrued expense

5,184

Payments for Rent

$ 7,149

$ 6,373

Incremental borrowing rate

8%

8%

Weighted average remaining lease term

1 year 6 months 7 days

Accounting Standards Update 2016-02 [Member]

Operating lease right of use asset

$ 66,201

Operating lease liabilities

$ 66,201

Common Stock [Member] | Consultant [Member]

Stock issued during period shares for services | shares

73,301

University of Jaen [Member]

Payment for services

$ 30,268

€ 25,837

Royalty Agreement Terms [Member]

Operating leases income statement revenue percentage

2%

License Agreement Terms [Member]

Operating leases income statement revenue percentage

5%

1-Year Collaboration Agreement [Member]

Payment for services

$ 59,508

€ 52,000

2-Year Collaboration Agreement [Member]

Payment for services

$ 35,145

€ 30,000

$ 45,775

€ 40,000

Royalty percentage

2%

2%

Research Agreement [Member] | University of Jaen [Member]

Payment for services

$ 53,806

€ 53,200

Consulting Agreement [Member]

Monthly Fee

$ 50,000

Stock fee percentage

9.90%

9.90%

Accrued expense

$ 608,423

Other liabilities

0

New Three-Year Operating Lease Agreement [Member]

Lessee operating lease term

3 years

Payments for Rent

$ 2,176

$ 3,000

From 2012 through the 2014 [Member]

Total litigation penalty amount

$ 10,000

Installment 1 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services | €

€ 5,000

Installment 1 [Member] | Research Agreement [Member]

Payment for services

$ 18,407

€ 18,200

Installment 2 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 5,858

€ 5,000

Installment 2 [Member] | Research Agreement [Member]

Payment for services

$ 8,091

€ 8,000

Installment 3 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 11,715

€ 10,000

Installment 3 [Member] | Research Agreement [Member]

Payment for services

$ 7,080

€ 7,000

Installment 4 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 11,715

€ 10,000

Installment 4 [Member] | Research Agreement [Member]

Payment for services

$ 10,114

€ 10,000

Installment 5 [Member] | Research Agreement [Member]

Payment for services

$ 10,114

€ 10,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative)																					1 Months Ended	3 Months Ended			12 Months Ended
	Jul. 05, 2023 USD ($) $ / shares shares	Oct. 26, 2022 USD ($)	Oct. 26, 2022 AUD ($)	Aug. 01, 2022 USD ($)	Aug. 01, 2022 AUD ($)	May 04, 2022 USD ($)	May 04, 2022 AUD ($)	Aug. 12, 2021 USD ($) shares	May 14, 2019 USD ($) $ / shares shares	May 14, 2019 AUD ($) shares	Mar. 16, 2018 USD ($)	Mar. 16, 2018 AUD ($)	Feb. 01, 2018 USD ($)	Feb. 01, 2018 AUD ($)	May 05, 2016 USD ($)	May 05, 2016 AUD ($)	Feb. 25, 2016 USD ($)	Feb. 25, 2016 AUD ($)	Feb. 25, 2015 USD ($)	Feb. 25, 2015 AUD ($)	May 31, 2019 shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2023 AUD ($) shares	Sep. 30, 2022 USD ($) shares	Jun. 30, 2023 USD ($) shares	Jun. 30, 2023 AUD ($) shares	Jun. 30, 2022 USD ($)	Jun. 30, 2022 AUD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 AUD ($)	Sep. 30, 2023 AUD ($)	Jul. 05, 2023 AUD ($)	Jun. 30, 2023 AUD ($)	May 05, 2016 AUD ($)
Related Party Transaction [Line Items]
Payments for Rent | $																						$ 7,149		$ 6,373
Investor loan, value | $																						70,800
Debt instrument interest rate	10%																															10%
Bonus payable																						$ 16,070	$ 25,000		$ 48,905	$ 73,387	$ 99,691	$ 144,166
Exercise price | $ / shares
Granted exercise price | $ / shares
Accrued salaries																						$ 69,101			64,627						$ 107,500		$ 96,000
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Payments form related party | $																														$ 221,890
Bonus payable																													$ 166,418	$ 422,610
Remaining bonus amount																						$ 53,312	$ 82,937		$ 71,929	$ 107,937	125,386	181,324
Restricted stock shares of common stock																					0.078
Letter Agreement [Member]
Related Party Transaction [Line Items]
Investor loan, value	$ 153,256																															$ 230,000
Term of agreement	3 years
Debt instrument interest rate	10%																															10%
Issue of warrants	15,000,000
Share price | $ / shares	$ 0.01
Nathanielsz Employment Agreement [Member]
Related Party Transaction [Line Items]
Expired date																			Feb. 25, 2019	Feb. 25, 2019
Base salary per month | $																				$ 25,000
Annual salary		$ 414,900	$ 600,000																$ 205,680	$ 300,000
Percentage of pension of monthly salary																									9.50%	9.50%
Percentage of bonus of annual base salary																									200%	200%
Nathanielsz Employment Agreement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Annual salary				$ 414,900	$ 600,000						$ 274,240	$ 400,000
Percentage of bonus of annual base salary																			200%	200%					100%	100%
Nathanielsz Employment Agreement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Annual salary				309,313	400,000						$ 205,680	$ 300,000
Mrs. Nathanielsz [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Bonus payable | $																													$ 316,957
Employment Agreement [Member]
Related Party Transaction [Line Items]
Number of restricted stock unit vested, shares																						0.04	0.04
Employment Agreement [Member] | Initial Nathanielsz RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock shares of common stock									0.04	0.04												0.04	0.04	0.04
Employment Agreement [Member] | Additional Nathanielsz RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock unit issuable																									0.04	0.04
Services Agreement [Member]
Related Party Transaction [Line Items]
Number of restricted stock unit vested, shares																						0.02	0.02
Restricted stock unit issuable																									0.02	0.02
Services Agreement [Member] | Additional Kenyon RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock shares of common stock									0.02	0.02
Accounting Standards Update 2016-02 [Member]
Related Party Transaction [Line Items]
Operating lease, description															Such lease expired in May 2021 and was renewed for another one-year term from May 2021 to May 2022	Such lease expired in May 2021 and was renewed for another one-year term from May 2021 to May 2022
North Horizon Pty Ltd [Member]
Related Party Transaction [Line Items]
Lessee, operating lease, term of contract															5 years																			5 years
Operating leases rent expense, minimum rentals															$ 28,325	$ 39,600
Goods and service tax															2,575	$ 3,600
Payments for Rent																						$ 107,430	$ 167,129		$ 105,377	$ 158,129
North Horizon Pty Ltd [Member] | Three Year Operating Lease Agreement [Member]
Related Party Transaction [Line Items]
Lessee, operating lease, term of contract						3 years	3 years
Payments for Rent						$ 2,176	$ 3,000
Former Director [Member]
Related Party Transaction [Line Items]
Loans from related party | $																						28,581			29,630
Due to related parties | $																						$ 47,567			$ 49,314
Nathanielsz [Member] | North Horizon Pty Ltd [Member]
Related Party Transaction [Line Items]
Operating leases, future minimum payments due															$ 141,629																			$ 198,000
Mrs. Nathanielsz [Member]
Related Party Transaction [Line Items]
Annual salary													$ 80,904	$ 120,000
Payments form related party																											$ 5,577	$ 7,689
James Nathanielsz [Member]
Related Party Transaction [Line Items]
Payments form related party																	$ 3,205	$ 4,481
Mr. Nathanielsz [Member] | Board of Directors [Member]
Related Party Transaction [Line Items]
Officers compensation				$ 96,810	$ 140,000			$ 177,840
Debt conversion, converted instrument, shares issued								5,928,000
Mr. Nathanielsz [Member] | Employment Agreement [Member]
Related Party Transaction [Line Items]
Annual salary									$ 309,313	$ 400,000
Agreement term									3 years	3 years
Option purchase shares									0.04	0.04
Exercise price | $ / shares									$ 4,675,000
Market price									110%	110%
Granted exercise price | $ / shares									$ 4,250,000
Option term									10 years	10 years
Dr. Kenyon [Member] | Services Agreement [Member]
Related Party Transaction [Line Items]
Annual salary									$ 41,580	$ 54,000
Agreement term									3 years	3 years
Option purchase shares									0.02	0.02
Exercise price | $ / shares									$ 4,250,000
Market price									100%	100%
Option term									10 years	10 years
Dr. Kenyon [Member] | Cancellation Agreement [Member]
Related Party Transaction [Line Items]
Debt conversion, converted instrument, shares issued								3,420
Cancellation of accrued salary | $								$ 102,600

CONCENTRATIONS AND RISKS (Detai

CONCENTRATIONS AND RISKS (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
Concentration Risk [Line Items]
Discounts and debt issuance cost	$ 34,500	$ 33,750
Proceeds from convertible debt	$ 220,000	$ 345,750
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender One [Member]
Concentration Risk [Line Items]
Concentration risk percentage	30%	29%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Two [Member]
Concentration Risk [Line Items]
Concentration risk percentage	14%	27%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Three [Member]
Concentration Risk [Line Items]
Concentration risk percentage	24%	44%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Four [Member]
Concentration Risk [Line Items]
Concentration risk percentage	32%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Receivable [Member]
Concentration Risk [Line Items]
Concentration risk percentage	100%		100%
Lender One [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	$ 150,000	$ 101,250
Lender Two [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	70,000	94,500
Lender Three [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	120,000	$ 150,000
Lender Four [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	$ 153,256

SCHEDULE OF FAIR VALUE MEASUREM

SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES (Details)	3 Months Ended
	Sep. 30, 2023
Measurement Input, Price Volatility [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	328
Measurement Input, Price Volatility [Member] | New Derivative Instruments [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	327.58
Measurement Input, Expected Term [Member] | Convertible Debt [Member] | Minimum [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, term	4 months 24 days
Measurement Input, Expected Term [Member] | Convertible Debt [Member] | Maximum [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, term	5 months 19 days
Measurement Input, Expected Term [Member] | New Derivative Instruments [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, term	6 months
Measurement Input, Risk Free Interest Rate [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	5.53
Measurement Input, Risk Free Interest Rate [Member] | New Derivative Instruments [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	5.55

SCHEDULE OF FAIR VALUE, ASSETS

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Platform Operator, Crypto-Asset [Line Items]
Embedded conversion option liabilities	$ 119,069	$ 423,209
Total	119,069	423,209
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto-Asset [Line Items]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto-Asset [Line Items]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto-Asset [Line Items]
Embedded conversion option liabilities	119,069	423,209
Total	$ 119,069	$ 423,209

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Beginning balance	$ 423,209
Initial fair value of embedded conversion option derivative liability recorded as debt discount	70,000
Initial fair value of embedded conversion option derivative liability recorded as derivative expense	77,721
Reduction of derivative liability upon debt conversion	(147,932)
Change in fair value included in statements of operations	(303,929)	$ (65,173)
Ending balance	$ 119,069

DERIVATIVE FINANCIAL INSTRUME_3

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Share price	$ 0.024
Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Convertible debt	$ 82,000	$ 75,300

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)

1 Months Ended

2 Months Ended

3 Months Ended

Oct. 20, 2023

Oct. 12, 2023

Aug. 23, 2023

Aug. 16, 2023

Sep. 21, 2022

Aug. 12, 2022

Oct. 03, 2019

Oct. 31, 2023

Nov. 30, 2023

Sep. 30, 2023

Sep. 30, 2022

Jul. 05, 2023

Jun. 30, 2023

Subsequent Event [Line Items]

Debt instrument face amount

$ 70,800

Interest payable current and non current

5,184

Conversion fees

1,437

Reclassification of put premium upon debt conversion

34,838

$ 133,646

Deemed dividend upon alternate cashless exercise of warrants

Debt instrument, interest rate, stated percentage

10%

Debt instrument debt default interest rate

24%

Penalty amount

30,000

Debt instrument unamortized discount

79,236

$ 38,994

GS Capital Partners, LLC [Member]

Subsequent Event [Line Items]

Interest payable current and non current

5,184

2,945

Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Debt instrument face amount

65,280

Debt instrument maturity date

Oct. 03, 2020

Debt instrument unamortized discount

88,846

$ 115,769

Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member]

Subsequent Event [Line Items]

Interest payable current and non current

2,488

Debt instrument, interest rate, stated percentage

800%

Debt instrument debt default interest rate

35%

Percentage of outstanding shares of common stock

150%

Debt outstanding principal percentage

22%

Penalty amount

$ 1,000

Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | Minimum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

110%

Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | Maximum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

129%

Percentage of outstanding shares of common stock

9.99%

Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]

Subsequent Event [Line Items]

Debt instrument face amount

$ 77,500

$ 71,500

$ 93,000

82,000

75,300

Interest payable current and non current

$ 887

$ 4,263

Debt instrument maturity date

Feb. 23, 2024

Mar. 21, 2023

Apr. 12, 2023

Debt instrument, interest rate, stated percentage

8%

8%

8%

Percentage of outstanding shares of common stock

4.99%

4.99%

Debt instrument unamortized discount

$ 5,000

$ 4,000

$ 5,000

Legal fees

$ 2,500

$ 2,500

$ 3,000

Conversion price, description

The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.04 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.02 per share in the event that the market price of the Common Stock trades below $0.03 per share for five consecutive trading days. In the event of a default under the Note and unless the Fixed Price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. Pursuant to the Note, in the event that such conversion price is below the par value of the Common Stock, the Company has agreed to take all steps to reduce such par value or conduct a reverse split of its Common Stock, as applicable. Notwithstanding the foregoing, such conversion price and lookback periods are subject to adjustment in favor of the Investor in the event the Company issues securities to another party with more favorable conversion terms, and such conversions are subject to a 4.99% beneficial ownership limitation (which may be increased to 9.9% upon 60 days’ prior written notice from the holder of the Note) and adjustments for mergers, consolidations, reorganizations and similar events set forth in the Note, other than a transfer or sale of all or substantially all Company assets. Pursuant to the Note, the Company is required to maintain an initial reserve of at least 400% of the number of Conversion Shares, subject to any increase of such reserved amount to reflect the Company’s obligations under the Note.

Such note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2 (the “September Fixed Price”). However, in the event the common stock trades below $1.40 per share for more than five consecutive trading days, then the September Fixed Price becomes $0.90 per share

The GS Capital Note was exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital by surrendering the same. GS Capital was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2.80 per share (the “Fixed Price”). However, in the event the common stock trades below $2 per share for more than five consecutive trading days, then the Fixed Price became $1.30 per share

Debt instrument increase principal percentage

20%

Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Minimum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

110%

Penalty amount

$ 250

Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Maximum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

125%

Penalty amount

$ 500

Common Stock [Member]

Subsequent Event [Line Items]

Shares issued for conversion of convertible debt

4,898,307

264,493

Reclassification of put premium upon debt conversion

Issuance of common stock for alternate cashless exercise of warrants, shares

2,282,000

158,399

Deemed dividend upon alternate cashless exercise of warrants

Subsequent Event [Member]

Subsequent Event [Line Items]

Debt instrument face amount

$ 37,800

Interest payable current and non current

2,354

Conversion fees

160

Reclassification of put premium upon debt conversion

$ 22,200

Deemed dividend upon alternate cashless exercise of warrants

$ 12,160

Subsequent Event [Member] | Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member]

Subsequent Event [Line Items]

Debt instrument face amount

$ 40,000

Debt issuance costs

$ 5,000

Debt instrument maturity date

Oct. 20, 2024

Debt instrument, interest rate, stated percentage

8%

Debt instrument debt default interest rate

35%

Percentage of outstanding shares of common stock

150%

Debt outstanding principal percentage

22%

Penalty amount

$ 1,000

Subsequent Event [Member] | Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | Minimum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

110%

Subsequent Event [Member] | Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | Maximum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

129%

Percentage of outstanding shares of common stock

9.99%

Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]

Subsequent Event [Line Items]

Debt instrument face amount

$ 61,000

Debt instrument maturity date

Apr. 12, 2024

Debt instrument, interest rate, stated percentage

8%

Debt instrument debt default interest rate

24%

Debt instrument unamortized discount

$ 3,500

Legal fees

$ 2,500

Conversion price, description

The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.015 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.01 per share in the event that the market price of the Common Stock trades below $0.0075 per share for ten consecutive trading days. In the event of a default under the Note and unless the Fixed Price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. Pursuant to the Note, in the event that such conversion price is below the par value of the Common Stock, the Company has agreed to take all steps to reduce such par value or conduct a reverse split of its Common Stock, as applicable. Notwithstanding the foregoing, such conversion price and lookback periods are subject to adjustment in favor of the Investor in the event the Company issues securities to another party with more favorable conversion terms, and such conversions are subject to a 4.99% beneficial ownership limitation (which may be increased to 9.9% upon 60 days’ prior written notice from the holder of the Note) and adjustments for mergers, consolidations, reorganizations and similar events set forth in the Note, other than a transfer or sale of all or substantially all Company assets. Pursuant to the Note, the Company is required to maintain an initial reserve of at least 400% of the number of Conversion Shares, subject to any increase of such reserved amount to reflect the Company’s obligations under the Note

Debt instrument increase principal percentage

20%

Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Minimum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

110%

Penalty amount

$ 250

Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Maximum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

125%

Penalty amount

$ 500

Subsequent Event [Member] | Series A Warrant [Member]

Subsequent Event [Line Items]

Alternate cashless warrant exercise price

$ 0.0037

Subsequent Event [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Shares issued for conversion of convertible debt

6,059,502

Contractual conversion price

$ 0.001

Issuance of common stock for alternate cashless exercise of warrants, shares

740,000